FLT3 and acute myeloid leukemia: This approach has strong translational potential to alter the AML therapeutic landscape, including with combination or sequencing approaches that support normal myeloid differentiation and tonal eradication of leukemic clones after cytotoxic or Venetoclax-based therapy, or in combination with other epigenetically targeted differentiation agents (e.g., Menin, FLT3, or IDH inhibitors) in non-APL AML.